特定益生菌组合治疗干眼症的有效性和安全性:一项随机、双盲、安慰剂对照试验
Efficacy and safety of a lactiplantibacillus plantarum and bifidobacterium bifidum complex for dry eye disease: a randomized, double-blind, placebo-controlled trial
一项随机、双盲、安慰剂对照试验评估了特定益生菌组合LB-101(Lactiplantibacillus plantarum NK151和Bifidobacterium bifidum NK175)在干眼症成人患者中的有效性和安全性。8周后,LB-101组泪膜破裂时间显著改善,某些症状评分也有所提高,但总体OSDI评分和其他客观眼部表面终点未见显著差异。
- Yengwoo Son1,
- Yoon-Jung Shin2,
- Seok-Won Jang3,
- Seung-Won Han3,
- Mi-Young Jung1,
- Dong-Hyun Kim2 &
- …
- Choul Yong Park1
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Abstract
Dry eye disease (DED) is a prevalent ocular condition associated with systemic inflammation, and the gut–eye axis has emerged as a potential therapeutic target. This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of LB-101, a probiotic complex comprising Lactiplantibacillus plantarum NK151 and Bifidobacterium bifidum NK175, in adults with DED. Eighty participants were randomized to LB-101 or placebo once daily for 8 weeks, of whom 62 participants completed the study and were included in the final efficacy analysis. After 8 weeks, the LB-101 group demonstrated a statistically significant improvement in tear break-up time compared to placebo (mean difference: 1.01 s, 95% CI 0.01–2.01, p = 0.047). Significant improvements were also observed in certain individual symptom-level Ocular Surface Disease Index (OSDI) items. However, total OSDI scores and most other objective ocular surface endpoints did not differ significantly between the groups. Exploratory gut microbiota analysis revealed a significant increase in Carnobacteriaceae and a decrease in the endotoxin-producing bacterial family Oxalobacteraceae in the LB-101 group. No serious adverse events occurred. In conclusion, oral administration of LB-101 for 8 weeks improved tear film stability and certain symptom-level OSDI items, although total OSDI and most objective endpoints remained nonsignificant, with exploratory microbiome findings supporting the therapeutic relevance of the gut–eye axis in DED.
Funding
This work was supported by the Medical Research Program (No. 2017R1A5A2014768) through the National Research Foundation of Korea (NRF), funded by the Ministry of Science and ICT, Korea. The funder had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Author information
Authors and Affiliations
Department of Ophthalmology, Samsung Medical Center,Sungkyunkwan University School of Medicine,, Seoul, Republic of Korea
Yengwoo Son, Mi-Young Jung & Choul Yong Park
Neurobiota Research Center, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea
Yoon-Jung Shin & Dong-Hyun Kim
PB Department, NVP Healthcare, Inc, Suwon, Republic of Korea
Seok-Won Jang & Seung-Won Han
Authors
- Yengwoo Son
- Yoon-Jung Shin
- Seok-Won Jang
- Seung-Won Han
- Mi-Young Jung
- Dong-Hyun Kim
- Choul Yong Park
Corresponding author
Correspondence to Choul Yong Park.
Ethics declarations
Competing interests
The authors declare no competing interests.
Use of Artificial Intelligence tools
During the preparation of this manuscript, the authors used Claude (Anthropic, claude.ai) to assist with manuscript drafting and editing, quality control review, and Python script development for supplementary statistical analysis. All AI-assisted content was critically reviewed, verified against source data, and approved by the authors. The authors take full responsibility for the integrity and accuracy of the work.
Ethics statement
This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Dongguk University Ilsan Hospital (IRB No. 2022-09-007-023). Written informed consent was obtained from all participants prior to enrollment.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Son, Y., Shin, YJ., Jang, SW. et al. Efficacy and safety of a lactiplantibacillus plantarum and bifidobacterium bifidum complex for dry eye disease: a randomized, double-blind, placebo-controlled trial. Sci Rep (2026). https://doi.org/10.1038/s41598-026-79278-4
Received: 15 June 2026
Accepted: 30 October 2026
Published: 13 November 2026
DOI: https://doi.org/10.1038/s41598-026-79278-4
Keywords
来源:Nature 健康护理主题 · nature.com